Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**RNF32 antisense RNA 1 (RNF32-AS1)** is a long noncoding RNA (lncRNA) transcribed from the opposite DNA strand of the RNF32 gene locus[1]. Antisense RNAs, such as RNF32-AS1, often function in the regulation of gene expression, either by interacting with the sense transcript of the gene from which they are derived or by modifying chromatin and transcriptional activity at the locus[4]. The specific functional, biological, and clinical roles of RNF32-AS1 remain poorly characterized, with no evidence as of the available search results for direct involvement in human disease, no reported interactions with drugs, and no defined mechanism of action as a therapeutic target. General roles for antisense RNAs include cis- or trans-regulation of gene expression, and they may influence molecular processes such as transcriptional interference or epigenetic modification[4]. There is no evidence in the current biomedical literature that RNF32-AS1 is an established therapeutic target or clinically utilized biomarker[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNF32 antisense RNA 1 (RNF32-AS1).